PortfoliosLab logoPortfoliosLab logo
CNCR vs. ARKG
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CNCR vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

ARKG

1D
-2.16%
1M
12.21%
YTD
17.36%
6M
14.32%
1Y
57.12%
3Y*
0.75%
5Y*
-15.45%
10Y*
7.24%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. ARKG - Yearly Performance Comparison


CNCR vs. ARKG - Sectors Allocation Comparison


Sectors
CNCR
ARKG

Healthcare

96.6%
99.2%

Financial Services

3.3%
0.5%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

CNCR
96.6%
ARKG
99.2%

Financial Services

CNCR
3.3%
ARKG
0.5%

Basic Materials

CNCR

-

ARKG

-

Communication Services

CNCR

-

ARKG

-

Consumer Cyclical

CNCR

-

ARKG

-

Consumer Defensive

CNCR

-

ARKG

-

Energy

CNCR

-

ARKG

-

Industrials

CNCR

-

ARKG

-

Real Estate

CNCR

-

ARKG

-

Technology

CNCR

-

ARKG

-

Utilities

CNCR

-

ARKG

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CNCR vs. ARKG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

ARKG
ARKG Risk / Return Rank: 3939
Overall Rank
ARKG Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 4040
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3535
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4545
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3535
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. ARKG - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


CNCRARKGDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.34

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

0.13

Drawdowns

CNCR vs. ARKG - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for CNCR and ARKG.


Loading charts...

Drawdown Indicators


CNCRARKGDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-83.59%

+83.59%

Max Drawdown (1Y)

Largest decline over 1 year

-27.51%

Max Drawdown (3Y)

Largest decline over 3 years

-51.96%

Max Drawdown (5Y)

Largest decline over 5 years

-80.18%

Max Drawdown (10Y)

Largest decline over 10 years

-83.59%

Current Drawdown

Current decline from peak

0.00%

-69.58%

+69.58%

Average Drawdown

Average peak-to-trough decline

0.00%

-35.86%

+35.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.46%

Volatility

CNCR vs. ARKG - Volatility Comparison


Loading charts...

Volatility by Period


CNCRARKGDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.89%

Volatility (6M)

Calculated over the trailing 6-month period

29.12%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

41.24%

-41.24%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

45.62%

-45.62%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

41.13%

-41.13%

CNCR vs. ARKG - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than ARKG's 0.75% expense ratio.


Dividends

CNCR vs. ARKG - Dividend Comparison

Neither CNCR nor ARKG has paid dividends to shareholders.


PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF
0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


On fees, ARKG is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.

ARKG is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.

CNCR and ARKG have nearly identical dividend yields, around 0.00%.

They also come from different issuers: Exchange Traded Concepts and ARK. Their fees differ too: 0.79% for CNCR and 0.75% for ARKG.

Portfolio Optimizer

Find the right allocation for CNCR and ARKG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer